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Background. A 19-year-old girl was diagnosed with systemic lupus erythematosus, arthritis, malar rash, 
positive antinuclear antibody test and high levels of antibodies to double-stranded DNA. Two months after 
diagnosis, the patient presented with a sudden drop in blood hemoglobin level. Several days later, she 
developed bloody sputum, rapidly progressive dyspnea and hypoxemia. High-resolution CT showed diffuse 
alveolar infiltrates in both lung fields.
Investigations. Physical examination, complete blood count, erythrocyte sedimentation rate, urinalysis, 
24-h urine protein excretion, fecal occult blood test, d-dimer test, acid hemolysis test, activated partial 
thromboplastin time and prothrombin time, direct and indirect Coombs tests, bone marrow smear, arterial 
blood gas, sputum smear and culture, and high-resolution CT scan of the chest.
Diagnosis. Diffuse alveolar hemorrhage associated with systemic lupus erythematosus.
management. The patient did not respond to pulsed methylprednisolone therapy (two course of 500 mg per day 
for 3 days) and immunoglobulins (20 g per day for 5 days). The patient was referred to a specialist treatment 
center for allogenic transplantation using umbilical cord-derived mesenchymal stem cells. She underwent 
transplantation with an infusion of 8 × 107 mesenchymal stem cells. After showing dramatic improvements 
in her clinic conditions, oxygenation level, radiographic and hematological status, the patient was discharged 
from hospital approximately 1 month after undergoing transplantation.
J. Liang et al. Nat. Rev. Rheumatol. advance online publication XX XXX 2010; doi:10.1038/nrrheum.2010.80
The case
a previously healthy 19-year-old girl presented to a local 
hospital with a 2-week history of arthritis, headache 
and hair loss. Physical examination showed a normal 
temperature and normal oxygen saturation level of 98% 
when breathing room air, malar rash and mouth ulcers. 
lung, heart and abdominal examinations were normal. 
laboratory analysis revealed a normal white blood cell 
count and hemoglobin level (11.5 g/dl; normal range 
11–15 g/dl), a low platelet count (50 × 109/l; normal range 
100–300 × 109/l), normal serum creatinine and serum 
albumin levels, a high erythrocyte sedimentation rate 
(esr; 56 mm/h, normal range 0–20 mm/h), and low levels 
of complement C3 (0.32 g/l; normal range 0.8–1.6 g/l) 
and complement C4 (0.02 g/l, normal range 0.2–0.4 g/l). 
urinalysis showed hematuria and protein uria. the mean 
24-h urine protein excretion was 349.3 mg (standard 
reference value <300 mg). in addition, the patient’s anti-
nuclear antibody (ana) was positive with high titer of 
1:1,200 (homogeneous pattern), and the level of anti-
bodies against double-stranded (ds) Dna was 564.6 iu/ml 
(standard reference value <50 iu/ml). on the basis of 
these findings a diagnosis of systemic lupus erythemato-
sus (sle) was made according to the american College of 
rheumatology criteria, and therapy was initiated compris-
ing intravenous methylprednisolone 40 mg per day and 
oral hydroxychloroquine 400 mg per day.
approximately 6 weeks later, the patient was free of joint 
pain and headache, but presented with pale mucosa and 
shortness of breath. a complete blood count showed a 
sudden drop in hemoglobin level from 11.5 g/dl to 5.7 g/dl, 
with a moderate increase in platelet count to 56×109/l. 
Fecal occult blood, d-dimer and acid hemo lysis tests 
were negative. activated partial thromboplastin time and 
prothrombin time were within normal limits, and direct 
and indirect Coombs tests were negative. a bone marrow 
smear showed marked hypercellularity. no evidence 
of active bleeding from the gastro intestinal, genitouri-
nary or nasal areas was found. two weeks later, methyl-
prednisolone 160 mg per day was added to the treatment 
regimen for 4 days. on cessation of methylprednisolone, 
the patient’s platelet count increased to 66 × 109/l and the 
esr was markedly reduced to 4 mm/h, but the hemoglo-
bin level dropped further to 3.9 g/dl. the patient had a 
sudden onset of cough and bloody sputum. auscultation 
revealed fine inspiratory crackles in both lung bases. a 
high-resolution Ct (HrCt) scan of the chest revealed 
bilateral, diffuse, alveolar infiltrates (Figure 1a). a sputum 
smear and culture were both negative for bacteria, fungi 
and acid-fast bacilli. Blood and urine cultures were also 
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negative for bacterial growth. a diagnosis of diffuse alveo-
lar hemorrhage (DaH) associated with sle was made, and 
the patient was admini stered pulsed intra venous methyl-
prednisolone 500 mg per day for 3 days and intravenous 
immunoglobulin 20 g per day for 5 days, in addition to 
prophylactic antibiotics and antifungal agents. multiple 
transfusions of washed red blood cells were also per-
formed. Despite these thera peutic measures, however, the 
patient’s pulmonary condition did not improve.
nine weeks after first being admitted, a repeat HrCt of 
the chest showed progressive lung infiltrates (Figure 1b). 
in addition, dyspnea and voluminous hemoptysis were 
observed. measurement of arterial blood gas showed 
severe hypoxemia with a partial pressure of oxygen of 
39 mmHg and an oxygen saturation level of 78% despite 
administration of 100% oxygen. the hemoglobin level 
increased slightly to 5.1 g/dl and the platelet count was 
normal (114 × 109/l). the patient then received non-
invasive mechanical respiratory support and 500 mg per 
day pulsed intravenous methylprednisolone treatment 
for a further 3 days. However, there were no improve-
ments in hypoxemia or dyspnea, and an HrCt scan 
showed no improvements (Figure 1c). the patient was 
transferred to a specialist treatment center for umbili-
cal cord-derived mesenchymal stem cell transplantation 
(uC-msCt) 4 days later.
at the time of admission to the specialist center, the 
patient looked pale and was tachypneic. Physical exami-
nation showed an elevated pulse rate of 98 beats per min, 
a raised respiratory rate of 30 breaths per min, and a low 
oxygen saturation level of 71% (normalized by a facial 
mask and noninvasive mechanical ventilation). Diffuse 
a
c d
b
Figure 1 | Chest HRCT scans before and after UC-MSCT. a | An initial HRCT scan of 
the chest shows bilateral, diffuse, alveolar infiltrates. b | Two weeks later, after the 
first course of treatment with pulsed methylprednisolone, a repeat HRCT scan of 
the chest shows progressive lung infiltrates. c | The second course of pulsed 
methylprednisolone 4 days later resulted in no improvements. d | Nine days after 
UC-MSCT, an HRCT scan of chest using a 3 mm collimation of the lung shows 
complete resolution of the lung infiltrates. Abbreviations: HRCT, high-resolution CT; 
UC-MSCT, umbilical cord mesenchymal stem cell transplantation.
crackles and tachycardia were found on auscultation, and 
lower extremity edema was also apparent. laboratory 
tests revealed a low hemoglobin level of 56 g/dl, a high 
reticulocyte count of 9.98% (normal range 0.5–1.5%), and 
low levels of C3 complement (0.44 g/l) and C4 comple-
ment (0.11 g/l). the esr, C-reactive protein (CrP) level 
and platelet counts were at normal levels. tests for anti-
neutrophil cytoplasmic antibodies, ana and anti-dsDna 
antibodies were all negative. urinalysis was normal and 
the 24-h urinary protein excretion was 376 mg.
For uC-msCt, 8 × 107 cells (2 × 106 cells per kg of the 
patient’s weight) were infused, and intravenous methyl-
prednisolone 40 mg per day was administered concomi-
tantly. Following treatment, the patient showed dramatic 
improvements in respiratory failure, oxygenation level, and 
radiographic and hematological status. one day following 
uC-msCt, the patient’s oxygen saturation level increased 
to 91% and arterial blood gas measures showed moderate 
improvements in hypoxia with a partial pressure of oxygen 
of 75 mmHg. over the following days, progressive improve-
ments were found in all of these parameters, and mechani-
cal respiratory support was removed 5 days after uC-msCt. 
an oxygen supplement (3 l/min) was administered by nasal 
catheter for a further 8 days. a follow-up HrCt scan of 
the chest 4 days later (9 days after uC-msCt) showed 
complete resolution of the lung infiltrates (Figure 1d). the 
oxygen supplement was stopped 3 days after the HrCt 
scan and oxygen saturation level stabilized at 96–98%. 
Hemoglobin levels fluctuated between 8.5 g/dl and 9.0 g/dl. 
a further 2 weeks later, laboratory data revealed a stable 
hemo globin level of 8.9 g/dl, a complement C3 level of 
0.79 g/l and a complement C4 level of 0.16 g/l. the patient 
was discharged from hospital 1 week later (approximately 
5 weeks after uC-msCt [Au:OK?]) in a stable condition 
with a regimen of prednisolone 30 mg per day.
approximately 6 weeks after being discharged, the 
patient returned for a scheduled follow-up visit. at this 
point, hemoglobin levels remained stable at 8.9 g/dl and 
the HrCt scan showed no obvious abnormalities. the 
patient was prescribed oral prednisone 20 mg per day, 
oral ciclosporin 150 mg per day and intravenous cyclo-
phosphamide 400 mg every other week.
three months after being discharged, and despite com-
bination therapy with prednisone, ciclosporin and cyclo-
phosphamide, the patient was readmitted for dyspnea and 
hemoptysis. an HrCt scan again revealed diffuse bi lateral 
pulmonary infiltrates. the patient received a second 
course of uC-msCt, with the same doses of prednisolone 
and immunosuppressive agents. the treatment was well 
tolerated and the patient recovered. she was discharged 
with gradual tapering of dosages of prednisolone and 
immunosuppressive agents. no further relapse of DaH 
had occurred at 5-month follow-up, and the patient con-
tinued to receive treatment with oral prednisolone 10 mg 
per day, oral ciclosporin 75 mg per day and intravenous 
cyclophosphamide 400 mg every other week.
Diagnosis
DaH is an unusual but serious and often fatal complica-
tion of sle, with an early mortality of at least 50%.1 Female 
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patients with an average age of 29 years are most com-
monly affected.2 the clinical presentation of DaH includes 
dyspnea, hemoptysis, hypoxemia and a sudden drop in 
hemoglobin level. HrCt often shows diffuse bilateral 
alveolar opacities. as described in this case, a diagnosis 
of DaH is usually made based on the presence of all these 
features and by the exclusion of other conditions such as 
antineutrophil cytoplasmic antibody (anCa)-associated 
vasculitis, Goodpasture syndrome (also known as anti-
glomerular basement membrane disease), thrombotic 
thrombocytopenic purpura and infection.
the etiopathogenesis of sle-associated DaH is not fully 
understood, although contributory factors are thought 
to include immune complex-mediated injury, thrombo-
cytopenia, vasculitis, congestive heart failure, renal failure 
and infection.3,4 the incidence of sle-associated DaH is 
reported to range from 1.9% to 5.7%.5,6 DaH can occur at 
any stage during the course of sle, and frequently presents 
with concurrent fever, arthritis, myositis, and peripheral 
neuropathy.6 although scores on the sle Disease activity 
index (sleDai) are raised in the presence of DaH, this 
has not been associated with increased mortality.7 the 
most common extrapulmonary manifestation of sle-
associated DaH is renal involvement, including clinical 
nephritis, nephritic syndrome or acute renal failure.7,8 in 
the present case, DaH developed when the symptoms 
of joint pain and headache treatment improved, and the 
signs and symptoms of DaH were the only manifesta-
tions of sle. sle disease activity, thrombocytopenia and 
renal failure were ruled out as possible major contributory 
factors for the development of DaH. we hypothesize that 
the patient had pulmonary capillaritis at the onset of sle. 
the lesions present in the lung did not respond to treat-
ment with high-dose intravenous methylprednisolone 
and, therefore, eventually developed into DaH.
Treatment
the therapeutic protocol for sle-associated DaH is 
not well defined. early treatment with high-dose intra-
venous corticosteroids is the mainstay of therapy, but this 
is not effective for every patient,9 including the patient 
described in this report. when the patient was referred 
for uC-msCt, her condition was so critical that treatment 
with cyclophosphamide, which often exerts a slow and 
moderate level of immunosuppression, was inade quate. 
after offering guidance and counseling to both the patient 
and her family, an agreement was reached to initiate an 
infusion of mesenchymal stem cells (msCs).
msCs are multipotential nonhematopoietic [Au:OK?] 
progenitor cells capable of differentiating into multiple 
lineages of cells, including osteoblasts, chondrocytes, 
myoblasts, adipocytes and endothelial cells. these cells 
are able to escape alloantigen recognition because of 
their low immunogenicity. However, they can also inhibit 
immune responses both in vitro and in vivo. this inhibit-
ing effect of msCs is related to the functional modulation 
of dendritic cells,10 t cells11,12 and natural killer cells.12,13 
the immunomodulatory properties of msCs provide 
a rational basis for their application in the treatment of 
immune-mediated diseases such as graft-versus-host 
disease and autoimmune diseases.14 in a previous study, 
our group demonstrated the functional abnormality of 
bone-marrow-derived msCs from patients with sle and 
lupus-prone mrl/lpr mice.15 we hypothesized that sle is, 
therefore, an msC-mediated disease, which prompted us 
to further investigate the therapeutic effect of msC trans-
plantation (msCt) in sle.
in a mouse model of lupus, we found that msCt was 
effective for inhibiting autoimmune disease,16 resulting in 
marked reductions of proteinuria and serum levels of crea-
tinine and antibodies against ds-Dna, and increased levels 
of complement C3. Histopathological examination showed 
marked decreases in the degree of glomerular sclerosis and 
interstitial fibrosis in msCt-treated mice compared with 
nontreated controls. immunohistochemical studies further 
revealed lowered expression of complement C3 in renal 
tissue after transplantation compared with lupus-prone 
mice treated with cyclophosphamide and with untreated 
mice. Following the observed clinical benefits of msCt in 
a mouse model of lupus, we tested the efficacy of msCt 
in four patients with sle refractory to cyclophosphamide 
therapy.17 all patients showed decreased sleDai scores 
and 24-h proteinuria, as well as improvements in serum 
levels of complement C3 compared with baseline. in addi-
tion, the percentage of regulatory t (treG) cells increased 
followed msCt. these short-term clinical data suggest 
that allogenic msCt could be a safe and feasible salvage 
therapy in these patients.17
in 2008, Zhao et al.18 suggested that msC engraftment 
can attenuate lung injury in a bleomycin-induced mouse 
model, and that this effect was dependent on the ability 
of the cells to engraft in the lung and to differen tiate 
into alveolar epithelial cells. in addition, Gupta et al.19 
reported that treatment with msCs in mice with experi-
mental endotoxin-mediated acute lung injury provided 
a significant survival advantage compared with no treat-
ment, possibly by reducing lung vascular permeability 
and the extent of pulmonary edema. the results of these 
studies encouraged our group to investigate whether 
administration of msCs would have beneficial effects in 
patients with sle and associated lung injury. uC-msCs 
were chosen because these cells share most of the charac-
teristics of bone marrow-derived msCs but with the 
Box 1 | Preparation of UC-MSCs
UC-MSCs were obtained from Jiangsu Stem Cell Bank, Jiangsu, China, and prepared 
for transplantation as follows: UCs were obtained from local maternity hospitals 
after normal deliveries. After having been minced into 1–2 mm3 fragments, UCs were 
incubated with 0.075% collagenase type II for 30 min and then 0.125% trypsin for 
a further 30 min with gentle agitation at 37 °C. The obtained cells were plated at a 
density of 1 × 106/cm2 in noncoated T-25 or T-75 cell culture flasks. The UC growth 
medium consisted of Dulbecco’s modified eagle’s medium with low glucose and 5% 
fetal bovine serum. After 3 days of culture, nonadherent cells were removed and 
the medium was changed twice-weekly thereafter. Once 60–80% confluence had 
been reached, adherent cells were replated at a density of 1–104/cm2 in UC growth 
medium for expansion. After two passages, cells were harvested that expressed 
[au:oK?] CD106, CD105, CD44 and CD29, but not CD34 or CD45. The capacity of 
MSCs to differentiate along adipogenic and osteogenic lineages was also assayed.
Abbreviations: MSC, mesenchymal stem cell; UC, umbilical cord.
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distinct advantages of higher proliferation, improved 
accessibility and lower risk of viral contamination.20,21 
Box 1 provides further details on the preparation of 
uC-msCs for infusion. in the present case, the patient 
showed considerable improvement 9 days after treat-
ment with uC-msCt. Considering that the patient had 
not responded to two cycles of high-dose steroids and 
showed rapid improvement after msCt, we suggest that 
it was the msCs, rather than the corticosteroids, that 
exerted a therapeutic effect.
the specific mechanisms by which msCt might 
improve sle-associated DaH are not known, and could 
be multifactorial. msCs could, for example, act in an 
immunomodulatory capacity by producing soluble factors 
induced upon stimulation. an imbalance of cytokine 
homeostasis is a prominent feature of both experimental 
lupus and human sle. experimental data have shown that 
msCs polarize the balance of type 1 and type 2 helper t 
(tH1 and tH2) cells via the secretion of cytokines such 
as interferon-γ and  interleukin-4.16 another mechanism 
of action of msCs could be related to an effect on the 
immune balance between treG cells and tH17 cells. treG 
cells play a pivotal role in the maintenance of dominant 
self-tolerance, and the frequency and function of treG 
cells has been shown to be considerably deficient in 
patients with active sle.22 By contrast, tH17 cells, which 
are inflammatory interleukin-17-producing cells, have 
been shown to augment inflammation and autoantibody 
production in the context of sle.23 we found that msCt 
can recover treG cells and downregulate tH17 cells.17 a 
third mechanism could be direct cell replacement by the 
differentiation of msCs [Au:OK?] into alveolar epithelial 
cells in the lesion. a recent study showed that msCs can 
differentiate into respiratory epithelial cells (that is, type ii 
alveolar cells).24 to some extent, therefore, the differentia-
tion of msCs to endothelial cells might reconstruct the 
structure of the nephron, thereby improving renal func-
tion. Presently, however, no data can confirm or refute 
these hypotheses.
Conclusions
DaH is a rare complication of sle that can occur at any 
time during the course of the disease. First-line treatment 
with high-dose corticosteroids has limited efficacy. in 
this Case study, we show that msCt was well tolerated 
by a patient with sle-associated DaH, and resulted in 
disease remission. Considering that the disease contin-
ued to deteriorate despite two cycles of treatment with 
high-dose corticosteroids, that the patient showed rapid 
and marked improvement after msCt, particularly 
after the second course of msCt following a relapse of 
DaH, and that the doses of prednisolone and immuno-
suppressive agents used were unchanged throughout the 
intervention, we believe that it was the msCt rather than 
the corticosteroid therapy that exerted a potent therapeu-
tic effect. msCt could, therefore, represent a promising 
future therapeutic strategy for treating DaH in patients 
with sle.
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